Imetelstat Study Blip Beats Geron’s Shares Down
Executive Summary
Shares in Geron dropped by nearly 20% to $2.30 on NASDAQ on Sept. 12 following interim clinical data for its lead product, the anticancer imetelstat, from trials conducted by its partner Janssen.
You may also be interested in...
Geron Sees Blockbuster Opportunity For Imetelstat, Eyeing Broader Market Than Reblozyl’s
The company reported positive results from its study in lower-risk myelodysplastic syndrome, where it forecasts a market potentially exceeding 30,000 in US and major European markets and generating up to $1.2bn in sales.
Imetelstat Trial Update Lift Geron, Despite Indecision By Partner J&J
News of continuation of myelofibrosis and myelodysplastic syndromes studies well-received in market, despite global partner J&J's apparent reluctance to commit to imetelstat for the long haul.
Misery In Myelofibrosis: Pacritinib Setback A Boost For Jakafi
With the commercial opportunity in the myelofibrosis market expected to double to over $1bn in the next five years, competition to Incyte/Novartis's Jakafi seems further away than ever as CTI BioPharma pulls the European regulatory filing for pacritinib.